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Abstract. Berberine is a natural isoquinoline alkaloid with 
significant antitumor activity against many types of cancer 
cells, including ovarian tumors. This study investigated the 
molecular mechanisms by which berberine differently affects 
cell growth of cisplatin (cDDP)-sensitive and -resistant and 
polyamine analogue cross-resistant human ovarian cancer 
cells. The results show that berberine suppresses the growth of 
cDDP-resistant cells more than the sensitive counterparts, by 
interfering with the expression of folate cycle enzymes, dihy-
drofolate reductase (DHFR) and thymidylate synthase (TS). In 
addition, the impairment of the folate cycle also seems partly 
ascribable to a reduced accumulation of folate, a vitamin which 
plays an essential role in the biosynthesis of nucleic acids and 
amino acids. This effect was observed in both lines, but espe-
cially in the resistant cells, correlating again with the reduced 
tolerance to this isoquinoline alkaloid. The data also indicate 
that berberine inhibits cellular growth by affecting polyamine 
metabolism, in particular through the upregulation of the key 
catabolic enzyme, spermidine/spermine N1-acetyltransferase 
(SSAT). In this regard, berberine is shown to stimulate the 
SSAT induction by the spermine analogue N1, N12 bisethyl-
spermine (BESpm), which alone was also able to downregulate 
DHFR mRNA more than TS mRNA. We report that the sensi-
tivity of resistant cells to cisplatin or to BESpm is reverted to 
the levels of sensitive cells by the co-treatment with berberine. 
These data confirm the intimate inter-relationships between 
folate cycle and polyamine pathways and suggest that this 
isoquinoline plant alkaloid could be a useful adjuvant thera-
peutic agent in the treatment of ovarian carcinoma.
Introduction
Ovarian cancer is the most lethal gynecological cancer in 
industrialized countries and is the fifth leading cause of cancer 
deaths in women. Ovarian carcinoma becomes often resistant 
to conventional systemic therapies even after the first treat-
ments and the prognosis for patients with advanced ovarian 
cancer remains poor (1).
The standard first-line treatment for ovarian cancer is a 
combination of paclitaxel and a Pt derivative drug such as 
cisplatin (cDDP) or carboplatin alone (2).
cDDP and its derivatives have been widely used to treat a 
variety of solid tumors including testicular, ovarian, head and 
cervical carcinoma (3). However, the appearance of resistant 
cells in the tumor limits its therapeutic effectiveness, thus 
cDDP is usually administered in combination with other 
drugs (4), lowering of drug dosages and consequently decrease 
side-effects, reducing the opportunity for the development of 
drug resistance by cancer cells (5).
Acquired resistance to cDDP and its derivatives is a multi-
factorial process involving many mechanisms, among these 
enhanced DNA synthesis and repair is the most common 
feature of resistance in almost all resistant cell lines studied. 
In this context, the overexpression of folate cycle enzymes 
dihydrofolate reductase (DHFR) and thymidylate synthase 
(TS) played an important role in a large survey of cDDP resis-
tance human ovarian carcinoma cell lines (6). Therefore, the 
discovery of drugs aimed at impairing the activity of these 
enzymes, thus circumventing cDDP-resistance, is of great 
interest.
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However, even chemotherapy based on combination of 
drugs is associated with significant side-effects, highlighting 
the need for therapeutic strategies that target tumor cells 
without compromising normal tissue function (7). Thus, the 
development of novel systemic agents from natural products 
with low toxicity and few side-effects is being actively pursued 
(8,9).
In this regard, cDDP has been recently combined with 
berberine, obtaining enhanced apoptotic cell death through a 
mitochondria/caspase-mediated pathway in HeLa cells (10).
Berberine is an isoquinoline alkaloid (Fig. 1) isolated 
from a variety of Chinese herbs, including Coptidis rhizoma, 
Phellodendron chinense schneid and Phellodendron 
amurense and other important medicinal plant species such 
as Berberis aristata and Berberis aquifolium and has diverse 
pharmacological actions such as antibacterial (11,12) and 
anti-inflammatory (13). The antineoplastic activities of 
berberine have been demonstrated against a variety of human 
cancer cells both in vitro and in vivo through suppression of 
tumor cell proliferation, or induction of tumor cell apoptosis 
(14,15). The pharmacologic effects depend on inhibition of 
DNA and protein synthesis, arrest of cell cycle progression 
(16,17). Besides, it has been reported that berberine has dual 
topoisomerase I and II poisoning activity and binds to double 
helical DNA with high affinity. Other potential targets of 
berberine hydrochloride include reactive oxygen species 
generation, mitochondrial function, RNA binding, the 
estrogen receptor, matrix metalloproteinase regulation and 
p53 activation (18-20). Nevertheless, it is relatively nontoxic 
to humans (21).
We have recently reported (22), that the binding at the 
AT-rich sequences of the minor groove of double-strand DNA 
of the natural antibiotic distamycin (23,24) was accompa-
nied by the downregulation of both dihydrofolate reductase 
(DHFR) and thymidylate synthase (TS) in cisplatin-sensitive 
and -resistant cell lines.
TS catalyzes the reductive methylation of dUMP by 
CH2H4PteGlu, generating dTMP and dihydrofolate (25). 
DHFR catalyzes the reduction of folate and 7,8-dihydrofolate 
(DHF) to 5,6,7,8-tetrahydrofolate (THF), utilizing NADPH as 
cofactor. Both reactions are essential steps in the biosynthesis 
of nucleotidic bases of DNA and thus important targets for 
chemotherapy (26).
Increasing body of evidence has suggested intimate inter-
relationships between folate cycle and polyamine pathways, 
since the polyamine key catabolic enzyme spermidine/
spermine N1-acetyl transferase (SSAT; EC 2.3.1.57) was 
identified as being one of the most affected genes in studies 
based on folate cycle inhibitors such as 5-FU (27-29). The 
polyamine pathway is an attractive target in the development 
of anticancer strategies (30), since the naturally occurring 
polyamines putrescine (Put), spermidine (Spd) and spermine 
(Spm) are essential for cell growth and differentiation and 
present elevated concentrations in cancer cells (31). In this 
regard, we have also reported that combinations of novel 
folate cycle inhibitors with quinoxaline structure and drugs 
that specifically target polyamine metabolism, such as diethyl-
derivatives of norspermine (DENSPM) or spermine (BESpm), 
have synergistic effect in killing cisplatin-sensitive and drug-
resistant daughter human ovarian cell lines (29). Besides, 
we have previously indicated the limited induction of SSAT 
activity as an important determinant of the reduced response 
to BESpm in the cDDP-resistant human ovarian cancer C13* 
cells (32).
In the present study, we investigated the effects of berberine 
on cDDP-sensitive human ovarian cancer cells and, for the first 
time, on the resistant counterparts and examined the func-
tional role of folate cycle enzymes and polyamine metabolism 
in berberine-induced cell growth inhibition. Besides, in this 
study the relationship between berberine-induced cell death 
and TS, DHFR and SSAT expression was explored, as well 
as the nature of the interaction between berberine with either 
cDDP or a polyamine analogue against ovarian carcinoma cell 
models.
Materials and methods
Chemical reagents. Berberine was provided by Dr P. Lombardi, 
Naxospharma (Milan, Italy) and was freshly dissolved in 
DMSO prior to addition to cell cultures. Cells treated with 
vehicle only [DMSO, maximum concentration, 0.5% (v/v) 
in media] served as control. [5-3H]dUMP (20 Ci/mmol), was 
purchased from Moravek Biochemicals (Brea, CA, USA). 
BESpm was kindly supplied by Hoechst Marion Roussel Inc. 
(Cincinnati, OH, USA). 1-[14C]acetyl coenzyme (1.89 GBq/
mmol) was purchased from Perkin-Elmer Italia (Milan, Italy). 
All other chemicals were purchased from Sigma-Aldrich S.r.l. 
(Milan, Italy), except when otherwise indicated.
Cell lines. The 2008 cell line was established from a patient 
with advanced cystadenocarcinoma of the ovary. The cDDP-
resistant C13* subline, which is ~15-fold resistant to cDDP, was 
derived from the parent 2008 cell line by monthly exposure 
to cDDP, followed by chronic exposure to step-wise increases 
in cDDP concentration (33). The cell lines were grown in 
monolayers in RPMI-1640 medium containing 10% heat-
inactivated foetal bovine serum and 50 µg/ml gentamycin 
sulphate. Vero cells, established from kidney cells of the 
African green monkey (Cercopithecus aethiops) and obtained 
from the Istituto Zooprofilattico (Brescia, Italy), were chosen 
as a control cell line (34). All cell media and serum were 
purchased from Lonza (Verviers, Belgium). Cultures were 
equilibrated with humidified 5% CO2 in air at 37˚C. All studies 
were performed in mycoplasma-negative cells, as routinely 
determined using the MycoAlert Mycoplasma detection kit 
(Lonza, Walkersville, MD, USA). Protein content in the assays 
was estimated using the Lowry method (35), unless otherwise 
indicated.
Cell growth assay. Cell growth was determined using a modi-
fied crystal violet assay (36). On selected days, the tissue 
culture medium was removed and the cell monolayer fixed 
with methanol and stained with 0.2% crystal violet solution in 
20% methanol for at least 30 min. After being washed several 
times with distilled water to remove excess dye, the cells were 
left to dry. The incorporated dye was solubilised in acidified 
isopropanol (1 N HCl:2-propanol, 1:10). After appropriate 
dilution, absorbance was determined spectrophotometrically 
at 540 nm. The extracted dye was proportional to the cell 
number. The percentage of cytotoxicity was calculated by 
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comparing the absorbance of cultures exposed to the drug to 
unexposed (control) cultures.
TS catalytic assay. Cells used for the enzyme assay were 
harvested by trypsinisation in an exponential growth phase, 
washed with PBS and used or stored at -20˚C. Cell pellets 
were thawed by the addition of ice-cold lysis buffer (200 mM 
Tris-HCl, pH 7.4, 20 mM 2-mercaptoethanol, 100 mM NaF and 
1% Triton X-100), sonicated (three x 5 sec) and subsequently 
centrifuged at 14,000 x g for 15 min at 4˚C. The supernatant 
was used for enzyme assays. The TS catalytic assay was 
conducted according to a previously reported method (37); the 
assay determined the catalytic activity of TS by measuring the 
amounts of 3H released during the TS catalyzed conversion 
of [5-3H]dUMP to dTMP. Briefly, the assay consisted of the 
enzymes in assay buffer (lysis buffer without Triton X-100) and 
650 µM 5,10-methylenetetrahydrofolate in a final volume of 
50 µl. The reaction was started by adding [5-3H]dUMP (1 µM 
final concentration, specific activity 5 mCi/mol), followed by 
incubation at 37˚C for 60 min and stopped by adding 50 µl of 
ice-cold 35% trichloroacetic acid. Residual [5-3H]dUMP was 
removed by adding 250 µl of 10% neutral activated charcoal. 
The charcoal was removed by centrifugation at 14,000 x g 
for 15 min at 4˚C and a 150-µl sample of the supernatant was 
assayed for tritium radioactivity by liquid scintillation counting 
in the liquid scintillation analyzer Tri-Carb 2100 (Packard). 
For each cell line, the linearity of [5-3H]dUMP conversion 
with respect to amount of protein and time was established.
DHFR catalytic assay. DHFR activity, measured as folate 
reductase, was determined by the [3H]-folate reductase assay, 
as previously described (38). Briefly, cells were harvested 
by trypsinization in an exponential growth phase, washed 
with PBS buffer and resuspended in 60 mM sodium citrate, 
pH 7.2 containing 10 mM 2-mercaptoethanol. Cell lysate was 
prepared by freeze thawing three times. The insoluble debris 
was removed by centrifugation at 14,000 x g for 15 min at 
4˚C. The supernatant was used immediately for enzyme 
assay after the determination of protein concentration by the 
method of Bradford, using the Bio-Rad reagent with bovine 
serum albumin as a standard (39). [3H]-folate (25 pmol) 
was preincubated with 1.5 µmol of dithionite for 10 min at 
37˚C in a total volume of 250 µl. Following this incubation 
60 nmol of NADPH and the enzyme preparation were added 
together with an appropriate amount of sodium citrate buffer 
pH 7.2 to reach a final volume of 500 µl. The reaction was 
performed for 60 min at 37˚C and stopped by adding, in 
sequence, 200 µl of a solution 0.027 M folic acid, 100 µl of 
0.1 N HCl and 200 µl of 0.3 N zinc sulfate. The yellow folate 
precipitate was pelletted by centrifugation at 16,000 x g for 
45 min and the tritium radioactivity of the supernatant was 
measured by adding 500 µl to 10 ml of Emulsifier Scintillation 
Plus cocktail (Perkin-Elmer Italia) in the liquid scintillator 
analyzer Tri-Carb 2100 (Packard). For each cell line, linearity 
of [3H]-folate conversion with respect to the amount of protein 
and time was established.
Western blotting. Cells were harvested, washed twice in 
ice-cold 1X PBS and resuspended in a buffer consisting 
of 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA 
(pH 8.0), 1% Triton X-100 and 0.1% SDS. Cells were lysed by 
freeze-thaw three times followed by sonication using three 
2- to -3-sec bursts. The insoluble debris was removed by 
centrifugation at 15,000 x g for 30 min. Protein concentra-
tions were determined using the Lowry method (35). Each 
protein sample (25 µg) was resolved by SDS-PAGE (12%). 
The gels were electroblotted onto hydrophobic polyvinylidene 
difluoride membranes (Hybond™-P PVDF, GE Healthcare 
Bio-Science, Uppsala, Sweden). Antibody staining was 
performed with a chemiluminescence detection system (ECL 
Plus Western Blotting Detection Reagent, GE Healthcare 
Bio-Science), using a 1:500 dilution of the mouse anti-human 
TS (TS106) monoclonal primary antibody (Invitrogen S.r.l., 
Milan, Italy), 1:1,000 dilutions of the mouse anti-human 
DHFR monoclonal antibody (Tebu-Bio, Milan, Italy) and 
1:1,000 of mouse anti-human β-tubulin antibody (Sigma-
Aldrich) in conjunction with a 1:3,000 dilution of horseradish 
peroxidase-conjugated sheep anti-mouse secondary antibody 
(GE Healthcare Bio-Science). Quantification of signal inten-
sity was performed by densitometry on a GS-800 calibrated 
densitometer (Bio-Rad) and analysed by using Quantity One 
software (Bio-Rad, CA, USA).
Real-time reverse transcription-PCR analysis. Total RNA was 
extracted from the cultured cells using TRI reagent (Sigma-
Aldrich). Reverse transcription was performed with 2 µg of 
total RNA using random primers (Promega, Milan, Italy) and 
M-MLV reverse transcriptase (Promega). Real-time RT-PCR 
was performed with 10 ng of cDNA using Power SYBR® 
Green PCR Master Mix [Applied Biosystems, Monza (MI), 
Italy] and an ABI-PRISM 7900 HT Sequence Detection 
System (SDS, Applied Biosystems), followed by a dissociation 
curve analysis and subsequent agarose gel electrophoresis to 
confirm amplification. The following primer sets were used: 
TS [NCBI reference sequence: NM_001071.1], forward: 5'-CAG 
ATTATTCAGGACAGGGAGTT-3', reverse: 5'-CATCAGAG 
GAAGATCTCTTGGATT-3'; DHFR [NCBI reference 
sequence: NM_000791.3], forward: 5'-TGCACAAATG 
GGGACGA-3', reverse: 5'-GGAAATATCTGAATTCAT 
TCCTGAG-3'; and GAPDH [NCBI reference sequence: 
NM_002046.3], forward: 5'-CAAGGTCATCCATGACAA 
CTTTG-3', reverse: 5'-GGGCCATCCACAGTCTTCTG-3'. 
SSAT primer sequences were, forward: 5'-TTATAGAGGCT 
TTGGCATAGGA-3', reverse: 5'-TCATTGCAACCTGGCT 
TAGA-3'. The amount of target, normalised to an endogenous 
reference (glyceraldehydes-3-phosphate dehydrogenase, 
Figure 1. Chemical structure of berberine.
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GAPDH) and relative to a calibrator (2008 cell line or untreated 
sample), was given by 2-∆∆Ct calculation (40). All experiments 
were carried out three times in triplicate; amplification plots 
were analysed using the ABI-PRISM 7900 HT SDS version 2.1 
software (Applied Biosystems).
[3H]folic acid uptake studies. [3H]folic acid uptake studies 
were performed according to previously published methods 
(41) with minor modifications. Briefly, one day after seeding, 
cells were treated for 72 h and then incubated for 10 min at 37˚C 
with 50 nM of [3H]folic acid, after a 20-min acidic treatment 
with stripping buffer (acetate pH 4.0) to remove endogenous 
folates bound to folate receptor (FR) at the cell surface. At the 
end of each experiment, cells were washed with 3X 1 ml of 
ice-cold PBS pH 7.4, to arrest the reaction. The cells were then 
solubilised with 0.3 ml 0.1% (v/v) Triton X-100 in 1% NaOH 
and placed at 37˚C overnight. An aliquot was transferred to 
scintillation vials containing 5 ml of scintillation cocktail. 
Radioactivity associated with the cells was quantified using 
a scintillation counter (TriCarb 2100, Packard, USA) and the 
protein content of each sample measured by the method of 
Lowry using bovine serum albumin as the standard.
Assay of SSAT activity. SSAT activity was measured 
as previously described (42). The cells were harvested, 
washed twice in PBS and suspended in a buffer containing 
10 mM tris(hydroxymethyl)aminomethane (pH 7.2) and 
1 mM dithiothreitol. This suspension was freeze-thawed 
twice, then cytosolic aliquots were incubated in 100 mM 
tris(hydroxymethyl)aminomethane (pH 8.0), 3 mM Spd and 
0.5 nmol 1-[14C]acetyl coenzyme A in a final volume of 50 µl 
for 10 min at 30˚C. The reaction was stopped by adding 10 µl 
of 1 M NH2-OH HCl and boiling in water for 3 min. The 
resulting samples were spotted onto P-81 phosphocellulose 
discs and radioactivity measured by scintillation counting. 
The amount of cytosol added to the final reaction mixture 
was adjusted to maintain the enzyme/substrate concentrations 
within the linear range. Enzyme activity is expressed as pmol 
[14C]acetylspermidine formed/min/mg protein.
Synergy analysis. The nature of the interaction between 
berberine and cisplatin or the polyamine analogue, combined 
simultaneously at a fixed ratio based on the different cell 
sensitivity to each drug, was determined using median-effect 
analysis (43), with the CalcuSyn ver. 2.0 software (Biosoft, 
Cambridge, UK), which calculates a non-exclusive case combi-
nation index (CI) for every fraction affected (FA), a measure 
of the drug interaction effects. CI values of <1 or >1 indicated 
synergy and antagonism, respectively, whereas a CI value of 1 
indicated additive effects of the drugs. Growth inhibition was 
assayed by the crystal violet dye assay to determine the dose-
response curves for each agent alone and in combination at a 
fixed ratio based on their IC50 values. Computer analysis of the 
dose-response curves was used to calculate the combination 
index (CI) at increasing levels of cell kill.
Statistical analysis. All values report the mean ± SEM, unless 
otherwise indicated. Statistical significance was estimated by 
two-tailed Student's t-test performed using Microsoft Excel 
software; a difference was considered significant at P<0.05 or 
P<0.01.
Results
Effect of berberine on the growth of cDDP-sensitive and 
-resistant cell lines. The dose-response curves of berberine in 
the cDDP-sensitive and -resistant cell lines (2008 and C13*) 
and Vero cells, depicted in Fig. 2A reveal a collateral sensi-
tivity of the cDDP-resistant line (IC50 = 5.3±0.6 µM versus 
IC50 = 14.5±1.2 µM in 2008 cDDP-sensitive cells) to the drug. 
Collateral sensitivity is a phenomenon which describes a cell 
population that is resistant to certain drugs and is more sensi-
tive to others. Berberine is also quite selective since it was 
much less cytotoxic against the non-tumorigenic Vero lineage. 
Figure 2. Cell growth inhibition by berberine. The dose-response curve of berberine (A) and the comparison of the IC50 values (µM) for cDDP, 5-FU and 
berberine in 2008, C13* and Vero cell lines (B) were determined after a 3-day exposure to the drugs. Results represent the mean of five separate experiments 
performed in duplicate. Error bars, SEM. The IC50 is defined as the concentration causing 50% growth inhibition in treated cells when compared to control.
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This feature along with the comparison between the efficacy 
of berberine and that of the two well-known anticancer drugs, 
cDDP and 5-FU, towards the three cell lines is displayed 
in Fig. 2B. As is evident, berberine is the least effective of 
the three drugs against the parental line, but the most active 
towards the resistant one. Noteworthy, the 50% growth reduc-
tion of Vero cells was not reached even with 40 µM berberine, 
but already with 10 µM cDDP and 4.8 µM 5-FU, indicating 
that berberine is more selective than the traditional chemo-
therapeutic compounds.
Modulation of TS and DHFR expression by berberine. We have 
previously reported that the cDDP-resistant human ovarian 
cancer cell line C13* showed collateral sensitivity towards two 
quinoxalinic compounds, new molecules designed as folate 
cycle enzyme inhibitors and structurally unrelated to the clas-
sical pteridine-like compounds and that this effect was related 
to folate cycle enzyme impairment (44). The resemblance of 
berberine effects with those of the two quinoxalines prompted 
us to evaluate and compare the effects of berberine on TS and 
DHFR expression in this acquired cDDP-resistant line and its 
parental line 2008.
It is interesting to note that, unlike traditional folate cycle 
inhibitors such as 5-FU, the cytotoxicity of berberine was 
accompanied by a greater inhibition of TS and DHFR expres-
sion in cell extracts from resistant cells than from sensitive 
ones. Therefore, the data reported in Fig. 3 explain, at least 
partly, the collateral sensitivity showed by C13* cells to 
berberine, since both TS and DHFR activities were decreased 
more in C13* than in 2008 cells by increasing drug concentra-
tions (Fig. 3A). TS activity was reduced at 10 µM berberine 
by 30 and 45% of the controls in 2008 and C13* cells, respec-
Figure 3. Effect of berberine on TS and DHFR expression in 2008 and C13* cells. (A) TS and DHFR activity and protein levels (B and C) were determined after 
a 72-h treatment with berberine 5 and 10 µM. hTS monomer, molecular mass 35 and hDHFR monomer, 21 kDa, were assayed in cell line extracts as described 
in Materials and methods. Equal lane loading was confirmed using a mouse anti-human β-tubulin antibody. The data taken from the densitometric scanning of 
the blots (C) were also graphed to better compare the differences of protein levels in the two cell lines (B). Results plotted represent the mean of three separate 
experiments performed in duplicate. Error bars, SEM. *P<0.05; as determined by Student's t-test vs control.
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tively; whereas, the residual DHFR activity after treatment 
was 70 and 45% of the respective controls.
This differential decrease of the enzyme activities reflected 
well the levels of both TS and DHFR proteins, which were 
both more downregulated in cDDP-resistant than in the sensi-
tive cells (Fig. 3B and C).
Notably, again unlike 5-FU (44), berberine reduced the 
level of TS monomeric form without inducing ternary complex 
formation, which is considered a mechanism of resistance to 
5-FU (45). Data from densitometric scanning indicated that 
residual TS protein levels were ~80 and 40% of control after 
treatment with the higher concentration of berberine in cDDP-
sensitive and in -resistant cells, respectively. Even DHFR 
protein was reduced by 30 and 55% in 2008 and C13* cells 
when compared to the respective controls.
Surprisingly, RT-PCR analysis revealed that only DHFR 
protein levels correlated with the respective decrease of DHFR 
mRNA amount, again more pronounced in the resistant line. 
In particular, the remaining DHFR mRNAs in 2008 cells 
were 70-80% of controls after treatment, while being 50-40% 
of control C13* cells. On the contrary, TS transcript was not 
significantly affected by drug exposure in either cell line 
(Fig. 4A).
To clarify whether the failure in impairing TS mRNA 
levels and the observed small difference between sensitive and 
resistant lines was also due to an effect of the drug on the turn-
Figure 4. Effects of berberine on TS and DHFR transcripts. (A) Dose-response effect of berberine on TS and DHFR mRNA expression in 2008 and C13* cells. 
RT-PCR analysis was performed in 2008 and C13* cells treated for 72 h with the indicated concentration of the compound. The amount of TS mRNA was nor-
malised to glyceraldehyde-3-phosphate dehydrogenase mRNA. Results represent the mean of three separate experiments performed in duplicate. Error bars, 
SEM. *P<0.05; as determined by Student's t-test vs control. The regression graphs of the kinetics of decay of TS mRNA (B) and DHFR mRNA (C) in 2008 and 
C13* cells pretreated for 72 h with berberine and then cotreated with the transcription inhibitor DRB (dichlorobenzimidazole riboside) 25 µg/ml for the times 
indicated. GAPDH mRNA levels also decreased with time (not shown). These blots are representative of findings from two experiments. Error bars, SEM.
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over of TS mRNA transcripts, we compared the half-life of TS 
and DHFR messengers in the two cell lines pretreated with 
berberine 5 µM for 72 h and then co-treated with the transcrip-
tion inhibitor dichlorobenzimidazole riboside (DRB) to shut 
off transcription. The rates of mRNA decay were then moni-
tored over a 24-h period. The data reported in Fig. 4B and C 
indicate that there is no difference in both basal TS mRNA 
and DHFR mRNA stability between sensitive and resistant 
cells. However, as is evident from the regression plots of 
Fig. 4B, treatment with berberine caused a remarkable slowing 
of the TS mRNA degradation rate in C13* cells, which turned 
over at a rate almost twice lower than that in sensitive cells. 
As a result, TS mRNA stability increased to a lesser extent 
in 2008 cells from a half-life of 14.5 h in controls to 18.3 h 
in berberine-treated cells, but to a much greater extent in the 
resistant line, from a half-life of 14.2 to 23.8 h, respectively. 
On the other hand, the rate of DHFR mRNA degradation was 
not affected by berberine in either cell line as the percentage 
of the remaining messengers was similar to the controls after 
drug exposure (Fig. 4C).
Noteworthy, in these conditions, berberine affected the 
cellular uptake of folic acid from culture medium (Table I). 
In particular, 10 µM berberine reduced the accumulation 
of 50 nM [3H]folic acid by ~13.3 and 27.6% in 2008 and 
C13* cells, respectively (from 163.3±4 to 141.4±7 fmoles/mg 
of protein in 2008 cells and from 182.8±9 to 132.9±11 fmoles/
mg of protein in C13* cells; n=3). Again, this differential effect 
correlates with the collateral sensitivity to berberine showed 
by the latter line.
Modulation of folate cycle enzymes and SSAT by combining 
berberine and Spm analogue. We have previously shown 
that these resistant cells are less responsive than their 
cDDP-sensitive counterparts the 2008 cells, to both the 
spermine analogue N1,N12-bisethylspermine (BESpm) 
(46) and the traditional anti-folates (44), when administered 
alone. Therefore, we also evaluated the effects of berberine 
combined with the polyamine analogue in the human ovarian 
cDDP-resistant C13* cells.
RT-PCR analysis revealed that 10 µM BESpm, concen-
tration chosen from the previously reported dose-response 
studies (32) and berberine did not significantly affect the 
TS mRNA levels in either cell line (Fig. 5A). However, both 
drugs decreased the level of DHFR mRNA in the cell lines, 
again particularly in resistant cells, but without potentiated 
effects when combined (Fig. 5B).
Similarly to berberine, the modulation of folate cycle 
enzymes by BESpm seems partly ascribable to the reduced 
folate uptake in the cell lines. As reported in Table I, 10 µM 
BESpm reduced the accumulation of 50 nM [3H]folic acid 
by ~17 and 24% in 2008 and C13* cells, respectively (from 
163.3±4 to 135.2±15 fmoles/mg of protein in 2008 cells and 
from 182.8±9 to 139.15±8 fmoles/mg of protein in C13* cells; 
n=3).
The effect on SSAT expression was evident. Fig.  6A shows 
that SSAT mRNA level was almost tripled and doubled by 
berberine in 2008 and C13* cells, respectively, reaching the 
Table I. Effect of berberine and BESpm on the uptake of 
[3H]folic acid in 2008 and C13* cells.
 2008 cells C13* cells
 ------------------------------------------ --------------------------------------------
Drugs fmoles/mg prot (%) fmoles/mg prot (%)
Ctrl 163.3±4 100 182.8±9 100
Berberine 141.4±7 86.59 132.9±11 72.70
10 µM
BESpm 135.2±15 82.79 139.15±8 76.12
10 µM
Figure 5. RT-PCR analysis of TS and DHFR mRNA levels after berberine and BESpm exposure. Cells (2008 and C13*) were treated for 72 h with 5 µM 
berberine in the presence or absence of 10 µM BESpm. The amount of TS mRNA (A) and DHFR mRNA (B) were normalised to glyceraldehyde-3-phosphate 
dehydrogenase mRNA. Results represent the mean of three separate experiments performed in duplicate. Error bars, SEM. *P<0.05; as determined by Student's 
t-test vs control.
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same induction caused by BESpm. Notably, berberine alone 
increased SSAT expression by itself but even more interest-
ingly, stimulated the SSAT overexpression by the polyamine 
analogue. In fact, when combined, berberine increased by 
2- and 1.5-fold SSAT mRNA level induced by BESpm in 
sensitive and resistant cells, respectively. As a consequence, 
SSAT activity was increased by berberine alone in both cell 
lines, but the drug over-induced the enzyme activity by the 
analogue additively in sensitive cells and synergistically in 
resistant cells (Fig. 6B).
Therefore, despite SSAT expression being less inducible 
by the analogue in the C13* resistant cells compared to sensi-
tive 2008 cells (46), in the presence of berberine, the reduced 
SSAT activity in the resistant line was reverted to induction 
level of the enzyme in sensitive cells by the co-treatment of 
berberine with Spm analogue.
  A   B
Figure 6. Effects of berberine and BESpm on SSAT expression. SSAT mRNA level by RT-PCR (A) and SSAT activity by radioactive assay (B) were performed 
in 2008 and C13* cells treated for 72 h with 5 µM berberine in the presence or absence of 10 µM BESpm. The amount of SSAT mRNA was normalised to 
glyceraldehyde-3-phosphate dehydrogenase mRNA. Results represent the mean of three separate experiments performed in duplicate. Error bars, SEM. 
*P<0.05; as determined by Student's t-test vs control.
Figure 7. Median-effect analysis of drug combinations at the proper constant ratios. Cells (2008) (left panels) and the C13* (right panels) were allowed 
to attach overnight and then simultaneously treated with berberine and with the indicated concentrations of cDDP (A) or BESpm (B) in 24-well plates. 
Following a 3-day exposure, cells were stained with crystal violet. Results are expressed as combination indexes (CIs), where CIs <1 indicate synergistic 
effects, CIs >1 indicate antagonistic effects, CIs=1 indicate additivity. Results represent the mean of three separate experiments performed in duplicate.
Error bars, SEM.
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Effects on cell growth by combining berberine with cDDP 
or with BESpm. Previous studies have shown that berberine 
potentiated the chemotherapeutic effect of cDDP by 
enhancing apoptosis in HeLa cells (10). Accordingly, we have 
ascertained the nature of the combination of berberine with 
cDDP, combined simultaneously in our cDDP-sensitive and 
-resistant cell model, determined by median-effect analysis. 
Cells were exposed to each drug alone and to their combina-
tions at constant ratio, deduced from IC50 values. The survival 
data were then plugged into the software CalcuSyn ver. 2.0 
(Biosoft), which provides the combination index (CI) for each 
level of cell kill. As depicted in Fig. 7A, the combination of 
cDDP and berberine resulted in mostly supra-additive effects 
in 2008 cells and mostly synergistic in C13* cells, confirming 
that berberine may facilitate cDDP activity, even in resistant 
cells.
We have also ascertained the nature of the combination of 
berberine with BESpm, combined simultaneously at a fixed 
ratio. As expected from the data of the modulation of the folate 
cycle enzymes and of the stimulated induction of SSAT expres-
sion, berberine synergistically increased cell growth inhibition 
by BESpm in both cell lines, even in resistant cells. Fig. 7B 
shows that berberine and Spm analogue combination is almost 
as effective in sensitive 2008 cells as in resistant C13* cells, 
producing synergistic cell killing in both lines.
Discussion
The natural isoquinoline berberine has shown antiproliferative 
activity against a variety of human cancer cells (14,15) and it 
has also been suggested as an anticancer drug for the treatment 
of ovarian cancer since it was shown to inhibit the prolifera-
tion of human ovarian tumor SVKO3 cells (47).
We show for the first time, that despite the cytotoxicity of 
berberine against a human ovarian cell line it is lower than 
that of the traditional anticancer drugs such as cDDP and 
5-FU, the isoquinoline is more effective than the chemothera-
peutic agents against the derived cDDP-resistant counterpart, 
C13* cells, which is even more sensitive to the alkaloid than 
parental cells, displaying collateral sensitivity. Besides, the 
natural compound was also more selective, showing scant 
toxicity towards non-tumorigenic Vero lineage.
Even if other mechanisms cannot be ruled out, the 
collateral sensitivity seems to correlate, at least partly, with 
the higher downregulation of TS and DHFR in C13* cells 
compared to 2008 cells. These effects are more relevant since 
this resistant line showed elevated expression of the folate 
cycle enzymes, thymidylate synthase (TS) and dihydrofolate 
reductase (DHFR), due to cisplatin-resistance phenotype (2).
The modulation of folate cycle enzyme expression and 
the cytotoxicity may be explained by the ability of berberine 
to bind nucleic acids. The binding of berberine to DNA and 
RNA has been defined sufficiently efficient and very similar 
to ethidium bromide to justify its use in spectrofluorimetric 
determination of the nucleic acids (48).
The anticancer activity of berberine appears to derive from 
its ability to form strong complexes with adenine-thymine base 
pair specific regions of nucleic acids, induce DNA damage and 
exert related effects such as telomerase inhibition, topoisom-
erase poisoning and inhibition of gene transcription (49-51). 
The antiproliferative activity was also recently ascribed to its 
ability to bind specifically to oligonucleotides and to stabilize 
DNA triplexes or G-quadruplexes via telomerase and topoi-
somerase inhibition (52,53). A non-classical intercalation 
model for berberine DNA binding has been confirmed (54). 
Very recently, substitution at the 13-position with unprec-
edented phenylalkyl groups remarkably enhanced the DNA 
binding action of berberine, providing insights into the 
importance of the 13-position substitution of berberine. This 
may be useful for the design and development of berberine 
structurally related new drugs with more specific and higher 
efficacy (55).
It has been reported that DNA intercalating agents and 
DNA minor groove-binders also bind to TS mRNA site 1 
construct (56). Moreover, we have also recently shown that 
the antibiotic distamycin, which binds at the relatively narrow 
AT-rich sequences of the minor groove of double-strand DNA 
(23,24), affects the expression of folate cycle enzymes even at 
the cellular level; this minor groove binder is able to modulate 
TS mRNA in vivo, thus affecting the translation and enzyme 
activity (22).
Similarly, berberine was shown to bind preferentially to 
AT rich sequences in DNA (57), also present in TS mRNA, 
thus accounting for the effect on folate enzymes expression 
and consequently on cytotoxicity.
Berberine binding to DNA probably also affects TS and 
DHFR gene transcription, but post-transcriptional effects such 
as stabilization affects TS mRNA levels rather than DHFR 
mRNA levels, suggesting a preferential binding to the former 
mRNA rather than the latter. In addition, the post-transcrip-
tional stabilization of TS mRNA in C13* cells, more than in 
2008 cells, may indicate differences in transcript  structures 
affecting berberine binding and/or differential resistance to 
mRNA catabolic enzymes between sensitive and resistant 
cells. However, in our experiments, berberine modulated the 
expression of TS and DHFR both at transcriptional and post-
transcriptional level, since DHFR mRNA level decreased 
more in C13* cells than in 2008 cells, whereas TS mRNA 
levels were almost not affected by berberine in the cell lines. 
Nevertheless, the final protein levels of the two enzymes 
and their activities were almost equally affected, but in 
particular in resistant cells. Therefore, TS expression appears 
to be the more differentially modulated by the alkaloid, as 
a lack of effect at transcriptional level was displayed both 
in sensitive and in resistant cells, along with a significantly 
reduced TS mRNA turnover only in C13* cells. Of note, the 
impairment of the folate cycle also seems partly ascribable 
to a reduction of folic acid accumulation in both cell lines. 
In particular, the resistant cells treated with berberine accu-
mulate less folic acid than sensitive cells when compared 
to the respective untreated controls. Folate is a member of 
vitamin B family and plays an essential role in cell survival 
by participating in the biosynthesis of nucleic and amino 
acids. Again, the slightly more compromised accumulation 
of this parent compound of purine and pyrimidine bases and 
amino acids contributes to explain the reduced tolerance to 
the isoquinoline alkaloid of the C13* cells.
DNA binding ligands, including minor groove binders 
such as distamycin and intercalators are considered ampli-
fiers of the DNA damaging effects of anticancer drugs (58). 
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Therefore, as distamycin synergistically enhanced cDDP cell 
killing (22), similarly, it is likely that berberine potentiated the 
action of cDDP, as evidenced by the fraction affected of the 
cells killed in synergy studies, by means of the downregula-
tion of TS and DHFR expression, thus preventing the new 
synthesis of damaged DNA. This mechanism is also supported 
by the reduced accumulation of folic acid, particularly in the 
resistant cells.
The upregulation of folate cycle enzymes in ovarian 
carcinoma cells (6), including this cDDP-resistant line (44) 
and the deficient SSAT expression previously reported (46) 
represent mechanisms of reduced sensitivity to better survive 
the cell inhibition caused by antifolates such as 5-FU and by 
polyamine depleting drugs, such as Spm analogues, but also 
the drug injury brought about by the alkylating agents such as 
cDDP. Therefore, our efforts were aimed to potentiate cDDP 
cytotoxicity even in cDDP-resistant cells by targeting the 
folate cycle and the polyamine metabolism, which have been 
shown to interrelate (27,28). Our group reported previously 
a synergistic increase in SSAT mRNA levels and cell death 
in response to the combination with novel TS inhibitors and 
SSAT inducers (29).
We report now, that the combination of berberine and 
the Spm-analogue BESpm modulates folate cycle enzymes, 
as reflected in the reduction of DHFR mRNAs in particular; 
whereas TS mRNAs were affected only to a lesser extent and 
in resistant cells, confirming that interrelations exist between 
these two metabolic pathways in this cell model. The data 
reported suggest that the synergistic inhibition of cell growth 
by berberine and BESpm combination involves DHFR gene 
downregulation more than TS gene, again mainly in resistant 
cells. This effect is accompanied by the induction of SSAT 
activity in the cell lines. However, the effect of this drug 
combination in sensitive cells seems to be mediated by the 
induction of polyamine catabolism rather than by folate cycle 
modulation, whereas, in resistant cells both metabolisms are 
more affected.
It is almost consolidated evidence that when both the 
folate cycle and the polyamine metabolism are concurrently 
modulated, cancer cell growth from different tumor types may 
be more validly treated. In particular, the combination of clas-
sical or novel inhibitors of TS and DHFR with inducing agents 
of the key catabolic enzyme of polyamine catabolism, SSAT, 
such as DENSpm or BESpm has proven therapeutic efficacy 
against tumor cell lines (27-29).
Accordingly, our results show that the co-treatment with 
berberine and BESpm, which caused DHFR downregulation 
and SSAT induction, resulted in a synergic cell killing in 
both lines, reverting the sensitization of resistant cells to the 
Spm analogue to the level of the sensitive counterpart. This 
evidence, correlating with the synergic induction of SSAT 
activity by drug combination is particularly important in 
resistant cells, since the cDDP-resistance phenotype conferred 
defective basal SSAT expression in C13* cells in comparison 
to parental 2008 cells and thus a reduced sensitivity to the 
induction of SSAT activity and cell growth inhibition by the 
polyamine analogues (29,46).
The consequent polyamine depletion caused by SSAT 
induction by berberine and BESpm combination may facili-
tate DNA intercalation by berberine, along with decreased 
DNA aggregation leading to relaxation of chromatin struc-
ture (59). This may favour the interaction and the effects of 
the analogue with DNA, partly accounting for the enhanced 
cytotoxicity of the combinations. In addition, the enhanced 
induction of polyamine catabolism leads to increased acety-
lated Spm or Spd concentration and to elevation of reactive 
oxygen species (29,60), which correlating with Spm deple-
tion, may initiate the apoptotic cascade and account for 
synergistic interactions.
Moreover, decarboxylated S-adenosylmethionine (SAM) is 
an essential precursor in the formation of both spermidine and 
spermine. SAM is formed from methionine through the addi-
tion of adenosine. Because 5-methyltetrahydrofolate donates a 
methyl group to homocysteine to produce methionine, folate 
deficiency may decrease polyamine synthesis (61). Therefore, 
BESpm may cause polyamine depletion both by the well-
known direct action on the enzymes of polyamine metabolism 
and by reducing folate uptake by cells, particularly by resistant 
ones.
In conclusion, our data show for the first time that a 
cDDP-resistant and polyamine analogue cross-resistant cell 
line is more sensitive to berberine than the parental cell line. 
This collateral sensitivity is partly attributable to a more 
pronounced downregulation of folate cycle enzymes in cDDP-
resistant than in the sensitive cells. These data also show that 
berberine is more effective against resistant cells than cDDP or 
5-FU and even more selective than the traditional anticancer 
drugs. Besides, we demonstrate that the natural compound 
berberine enhances the cell growth inhibition caused by cDDP 
and confirm the interrelationship between folate cycle and 
polyamine metabolism, since SSAT expression was upregu-
lated by the combination of berberine and an Spm analogue, 
accounting for the observed synergistic cell killing.
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